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Abstract  The  functional  beneﬁt  of  stent  retriever  thrombectomy  in  acute  ischemic  stroke
has been  clearly  demonstrated  in  recent  positive  MR  CLEAN,  ESCAPE,  EXTEND-IA,  SWIFT  PRIME,
REVASCAT and  THRACE  trials.  Thrombectomy,  in  association  with  intravenous  thrombolysis,
should now  be  offered  to  patients  with  documented  occlusion  of  the  distal  internal  carotid  or
proximal middle  cerebral  arteries,  with  a  relatively  normal  unenhanced  computed  tomography
(CT), and  within  6  hours  after  the  onset  of  symptoms.  Thrombectomy  results  in  a  mean  absolute
decrease  in  handicap  of  22%  (14  to  31%).  Of  the  3  up  to  8  patients  treated,  1  is  independent  at
3 months  according  to  the  initial  selection.  In  case  of  a  contraindication  to  thrombolysis,  early
primary thrombectomy  should  be  considered.  In  acute  basilar  artery  occlusion,  thrombectomy
should be  performed  alone  or  combined  with  thrombolysis.  In  an  effort  to  increase  the  number
of patients  treated,  a  very  rapid  transfer  to  interventional  neuroradiology  centers  is  mandatory.
In the  future,  thrombectomy  should  be  evaluated  in  patients  with  distal  arterial  occlusion,  or
beyond 6  hours  after  the  onset  of  symptoms,  or  when  the  time  of  symptoms  onset  is  unknown.© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.∗ Corresponding author. DHU IRIS, department of interventional neuro
de Lyon, 59, boulevard Pinel, 69677 Bron, France.
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The  goal  of  treatment  in  the  acute  phase  of  ischemic
troke  is  to  obtain  rapid  and  complete  arterial  recanaliza-
ion,  [1]  in  order  to  reperfuse  the  parenchyma,  which  is
n  the  ischemic  penumbra,  and  prevent  progression  to  cel-
ular  necrosis  [2].  Intravenous  (IV)  thrombolysis  with  the
issue  plasminogen  activator  (altephase,  t-PA)  has  been
he  only  proven  treatment  for  the  ﬁrst  4  h  30  after  the
nset  of  symptoms  [3].  A  meta-analysis  including  6756
atients  showed  that  IV  thrombolysis  administered  within
he  ﬁrst  4  h  30  after  the  onset  of  symptoms  signiﬁcantly
mproved  the  clinical  outcome,  the  earlier  it  was  admin-
stered,  the  better  (odds-ratio  [OR]  =  1.75;  95%  conﬁdence
nterval  [95%  CI]  =  1.35—2.27)  [4].  However  the  efﬁcacy
f  IV  thrombolysis  is  limited  by  the  low  rate  of  recanal-
zation  in  proximal  arterial  occlusions  (30%  for  an  M1
cclusion  of  the  middle  cerebral  artery  [MCA]  and  8%  for
cclusion  of  the  internal  carotid  artery  [ICA])  [5], a  nar-
ow  window  of  time  and  a  number  of  contraindications
recent  surgery,  hemostatic  disorders,  or  history  of  hem-
rrhagic  stroke).  Since  it  was  shown  to  be  beneﬁcial  20
ears  ago,  no  other  medication  or  technique  has  been
hown  to  signiﬁcantly  reduce  the  neurological  handicap.
lthough  tolerance  was  similar  to  IV  t-PA  in  the  IMS  3,
R  RESCUE  and  SYNTHESIS  trials  [6—8], the  beneﬁt  of
ntra-arterial  mechanical  thrombectomy  was  not  conﬁrmed
efore  the  arrival  of  ‘‘stent  retrievers’’.  ‘‘Stent  retriev-
rs’’  represent  major  therapeutic  progress  because  they
re  signiﬁcantly  more  effective  than  earlier  devices  (for
xample  MERCI  retriever  device)  making  it  possible  to  sig-
iﬁcantly  improve  the  neurological  prognosis  at  3  months
9,10].
The  goal  of  this  review  was  to  present  the  results  of
echanical  thrombectomy  (MT)  by  ‘‘stent  retriever’’,  to
escribe  the  main  clinical  and  radiological  parameters  inﬂu-
ncing  prognosis  and  to  imagine  the  main  situations  for  the
se  of  this  technique  (contraindication  to  IV  thrombolysis,
asilar  artery  occlusion.  .  .).
ivotal therapeutic trials on stent
etrievers
he  clinical  beneﬁt  of  MT  by  ‘‘stent  retriever’’  was  ﬁrst
eported  in  December  2014  in  the  randomized  clinical  trial
he  Multicenter  Randomized  Clinical  Trial  of  Endovascular
reatment  for  Acute  Ischemic  Stroke  in  the  Netherlands
MR  CLEAN),  which  compared  the  best  medical  treatment
IV  thrombolysis  within  4  h  30  after  the  onset  of  symp-
oms  in  case  of  no  contraindications)  to  MT  in  association
ith  IV  thrombolysis  in  patients  presenting  with  conﬁrmed
schemic  stroke  of  the  distal  internal  carotid  and/or  the
roximal  middle  cerebral  artery  (Table  1)  [11].  Femoral
uncture  had  to  be  performed  within  6  hours  after  the  ﬁrst
ymptoms.  Diagnosis  of  stroke  was  based  on  non-enhanced
ead  CT  and  CT  angiography.  Most  patients  had  undergone
V  thrombolysis  (89%)  before  the  procedure.  The  trial  was
topped  after  500  patients  had  been  included  (267  patients
n  the  thrombolysis  group  and  233  patients  in  the  MT  group).
V  thrombolysis  was  begun  after  85  min  in  the  MT  group
nd  87  min  in  the  thrombolysis  group,  and  femoral  punc-
ure  lasted  260  min  in  the  MT  group  (or  2  hours  and  55  min
a
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fter  thrombolysis)  (Table  2).  This  study  showed  that  MT  (by
‘stent  retriever’’  in  97%  of  the  cases)  resulted  in  an  abso-
ute  beneﬁt  of  13.5%  compared  to  IV  thrombolysis  alone
Rankin  score  [mRS]  ≤  2 at  3  months  32.6%  compared  to
9.1%;  OR  =  1.67,  95%  CI  =  1.21—2.3)  (Fig.  1).  The  median
IHSS  (NIH  stroke  scale)  score  at  24  hours  and  at  7  days  was
igniﬁcantly  lower  in  the  MT  group  (13  vs.  16  at  24  hours,  8
s.  14  at  7 days).  The  number  of  complications  in  the  MT
roup  was  similar  because  the  risk  of  symptomatic  hem-
rrhagic  stroke  (with  the  same  deﬁnition  as  that  in  the
CASS  3  study  [3])  was  7.7%  following  MT  (compared  to
.4%  in  the  IV  thrombolysis  group  alone).  Three-month  mor-
ality  was  not  different  in  the  two  study  arms  (18.9%  vs.
8.4%  at  30  days).  However,  stroke  in  a  new  territory  was
eported  in  5.6%  of  the  patients  after  MT  due  to  fragmen-
ation  of  the  clot  during  removal  (vs.  0.4%  after  IV  t-PA
lone).
In  2015,  four  randomized  controlled  trials,  Endovascular
reatment  for  Small  Core  and  Anterior  Circulation  Proximal
cclusion  With  Emphasis  on  Minimizing  CT  to  Recanaliza-
ion  Times  (ESCAPE),  Extending  the  Time  for  Thrombolysis  in
mergency  Neurological  Deﬁcits-Intra-Arterial  (EXTEND-IA),
olitaire  With  the  Intention  for  Thrombectomy  as  Primary
ndovascular  Treatment  Trial  (SWIFT  PRIME),  Randomized
rial  of  Revascularization  With  the  Solitaire  FR  Device  Versus
est  Medical  Therapy  in  the  Treatment  of  Acute  Stroke  Due
o  Anterior  Circulation  Large  Vessel  Occlusion  Presenting
ithin  Eight  Hours  of  Symptom  Onset  (REVASCAT)  also  con-
rmed  the  functional  beneﬁt  of  MT  associated  with  IV
hrombolysis  in  proximal  artery  occlusion  [12—15]. ESCAPE
as  stopped  early  after  inclusion  of  315  patients  due  to  a
ositive  intermediate  analysis  [12].  Although  the  time  win-
ow  was  12  hours,  rapid  management  was  essential  because
he  delay  between  radiological  diagnosis  and  femoral  punc-
ure  was  1  hour.  A  better  clinical  outcome  (mRS  ≤  2  at  3
onths)  was  observed  in  the  MT  group  (53.0%  vs.  29.3%;
R  =  3.1,  95%  CI  =  2.0—4.7)  as  well  as  a  signiﬁcant  decrease
n  mortality  (19%  vs.  10.4%).  The  beneﬁt  of  MT  persisted
n  the  different  subgroups  (patients  older  than  80,  initial
IHSS  >  19,  patients  treated  after  6  hours).  One  out  of  3
atients  undergoing  thrombectomy  had  an  improved  mRS.
ne  out  of  4  patients  undergoing  thrombectomy  was  inde-
endent  (mRS  ≤  2  at  3  months)  EXTEND-IA  was  a  phase  2
rial  that  analyzed  the  ischemic  penumbra  before  treatment
CT  perfusion)  and  evaluated  early  reperfusion  and  neuro-
ogical  improvement  on  day  3  [13]. This  study  was  stopped
arly  because  of  a  positive  intermediate  analysis  after  ran-
omization  of  the  ﬁrst  70  patients.  A  favorable  outcome
mRS  ≤  2  at  3  months)  was  obtained  in  71%  of  the  patients  in
he  MT  arm  compared  to  40%  in  the  control  group  (P  <  0.01;
umber  of  patients  to  be  treated  =  3).  SWIFT  PRIME  was
topped  early  after  a  positive  intermediate  analysis  of  the
rst  196  patients  [14].  The  patients  were  selected  based  on
T  or  magnetic  resonance  (MR)  (CT  or  MR  perfusion  with
he  RAPID  software  for  the  ﬁrst  71  patients)  and  unlike  pre-
ious  studies,  tandem  occlusions  were  exclusion  criteria.  A
avorable  clinical  outcome  was  signiﬁcantly  more  frequent
n  the  MT  group  (60.2%  vs.  35.5%,  P  <  0.001).  REVASCAT  was
lso  discontinued  early  by  the  data  and  safety  monitor-
ng  board  [15].  The  number  of  independent  patients  at  3
onths  signiﬁcantly  increased  after  MT  (43.7%  vs.  28.2%;
R  =  2.1).
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Table  1  Major  inclusion  criteria.
Trials  Country  Date  Age  NIHSS  Delay
(h)
Stent
retriever
(%)
Occlusion
location
Imaging
results
MR  CLEAN
[11]
Netherlands  12/10—03/14  ≥  18  ≥  2  6  81  ICA,  M1,
M2
CT
ESCAPE  [12] Canada  02/13—10/14 ≥  18 >  5 12 86  ICA,  M1  CT,
ASPECTS  ≥  6,
good
collaterals
and  60  min
between
CT-femoral
puncture
EXTEND-IA
[13]
Australia  08/12—10/14  ≥  18  ≥  0  8  100  ICA,  M1,
M2
CT  perfusion
(mis-
match  +  stroke
vol-
ume  <  70  mL)
SWIFT  PRIME
[14]
International  12/12—11/14  18—80  8—29  6  100  ICA,  M1  CT/MRI,
ASPECTS  ≥  7
et  femoral
puncture
within  90  min
of  imaging
REVASCAT
[15]
Spain  11/12—12/14  18—85  ≥  6  8  100  ICA,  M1,
M2
CT/MRI,
ASPECTS  ≥  7
or  6a
ICA: distal portion of the internal carotid artery (siphon and terminus); M1, M1: segment of the middle cerebral artery; M2, M2: segment
of the middle cerebral artery; NIHSS: NIH stroke scale.
a
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aASPECTS ≥ 7 with CT and ASPECTS ≥ 6 with MRI.
Selection by imaging
MT  is  indicated  in  patients  presenting  with  occlusion  of
the  brain  proximal  artery  whether  it  is  the  intracranial
internal  carotid  artery  or  the  proximal  middle  cerebral
artery  (M1  or  M2  segments  in  certain  trials).  It  is  therefore
mandatory  to  perform  MR  angiography  or  CT  angiography  to
conﬁrm  the  site  of  occlusion.  If  the  patient  is  transferred,
non-invasive  vascular  imaging  should  be  performed  in  the
primary  care  center  so  the  patient  can  be  brought  directly
to  the  angiography  room.  The  IMS  3  study  also  found  that
i
b
p
Table  2  Initial  characteristics  of  patients.
TM/CTL  MR  CLEAN  [11]  ESCAPE  [12]  
Number  of  patients  233/267  165/150  
Median  initial  NIHSS  17/18  16/17  
rt-PA  IV  before  TM  (%)  87  76  
M1  occlusion  (%)  66  68  
Tandem  occlusion  (%)  32  13  
Delay  to  reperfusion  (min)  260  241  
NNT  (mRS  ≤  2  at  3  months)  8  4  
sICH  (%) 7/6  4/3  
TM: thrombectomy group; CTL: control group; sICH: symptomatic intrandovascular  treatment  was  beneﬁcial  in  the  subgroup  of
atients  with  documented  arterial  occlusion  by  initial  non-
nvasive  imaging  [16].  In  the  ESCAPE  trial,  a  multiphase  CT
ngiography  was  performed  to  identify  patients  presenting
ith  moderate-to-good  collateral  circulation,  making  it  pos-
ible  to  temporarily  control  extension  of  ischemia  in  time
nd  space  [12,17].The  cerebral  parenchyma  beyond  this  occlusion  is  in
schemic  penumbra  and  can  survive  for  a certain  time
ecause  of  the  creation  of  pial  anastomoses  to  com-
ensate  for  hypoperfusion  [1]. Studies  in  tissue  viability
EXTEND-IA  [13]  SWIFT  PRIME  [14]  RESVASCAT  [15]
35/35  98/98  103/103
17/13  17/17  17/17
100  98  73
51  68  65
—  0  19
210  224  269
3  4  —
0/6  0/3  2/2
cerebral hemorrhage.
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Figure 1. A 73-year-old patient, receiving anticoagulants for arrhythmia, presenting with left hemiplegia at 19 h 45. At arrival, the
patient at 21 h 30 the patient had a NIHHS score of 19. Head MRI performed at 21 h 59 shows limited deep ischemia (hypersignal on
diffusion images, ASPECTS score 8, a—e) with proximal occlusion of the right middle cerebral artery (M1 segment) on time-of-ﬂight MR
(arrow, f). Arrival at the interventional neuroradiology unit at 23 h 00 and puncture of the femoral artery under local anesthesia at 23
h 19. Angiogram shows M1 occlusion by selective opaciﬁcation of the right common carotid artery (arrow, g). Complete revascularisation
(TICI 3) of the territory of the right middle cerebral artery after a third pass with the ‘‘stent retriever’’ at 00 h 15, or 56 min after femoral
puncture and 4 h 30 after the onset of symptoms (h—j). Unenhanced brain CT (k—m) performed at 24 hours shows deep right ischemia (+)
with no hemorrhagic complications.
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9re  important  to  select  candidates  [18].  Although  MR  is
ore  sensitive  than  CT  to  study  the  parenchyma,  [19]  in
ost  cases,  selection  has  been  based  on  a  simple  unen-
anced  CT  (MR  CLEAN,  ESCAPE,  EXTEND-IA).  However,  in
XTEND-IA,  a  CT  perfusion  was  systematically  performed
o  only  include  patients  presenting  with  small  volume
erebral  ischemia  (volume  <  70  mL)  with  surrounding  hypop-
rfused  tissue  (Tmax  >  6  seconds  [20],  mismatch  >  1.2)  [13].
erfusion  analysis  was  performed  with  automated  RAPID
oftware  to  minimize  analysis  time  [21].
Analysis  of  subgroups  in  MR  CLEAN  showed  a  beneﬁt  in  the
SPECTS  scores  ≥  5  (ASPECTS  5—7:  OR  =  1.97;  ASPECTS  8—10:
R  =  1.61).  On  the  other  hand,  this  beneﬁt  was  not  found  in
ore  extensive  stroke  (ASPECTS  score  0—4).  The  beneﬁts  of
T  have  therefore  been  conﬁrmed  in  patients  with  a  rela-
ively  small  volume  of  ischemia  (ASPECTS  score  ≥  5),  which
C
i
a
ws  also  true  for  IV  thrombolysis  because  the  initial  ischemic
olume  had  to  be  less  than  one  third  of  the  mean  middle
erebral  artery  territory  in  the  NINDS  [22], results  that  have
een  conﬁrmed  in  several  recent  studies  [23,24].
election by hours
o  obtain  these  results,  very  rapid  management  is  necessary.
he  delay  between  CT  and  femoral  puncture  was  60  min
nd  the  delay  between  CT  and  the  ﬁrst  reperfusion  was
0  min  in  ESCAPE  [12].  In  SWIFT  PRIME,  the  delay  between
T  and  femoral  puncture  was  90  min  [14]. Cerebral  recanal-
zation  was  obtained  early  in  most  of  these  5 trials,  within
pproximately  260  min.  The  beneﬁts  of  MT  in  MR  CLEAN
ere  dependent  upon  the  delay  to  reperfusion  (OR  =  3,  95%
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CI  =  1.6—5.6  for  a  delay  of  less  than  3.5  hours  between  the
ﬁrst  symptoms  and  reperfusion;  OR  =  1.5,  95%  CI  =  1.1—2.2
for  a  delay  of  6  hours)  [11].  These  results  justify  the  6-hour
treatment  window  after  the  onset  of  the  ﬁrst  symptoms  [25].
However,  in  ESCAPE,  the  beneﬁt  of  MT  compared  to  the  best
medical  treatment  persisted  in  the  49  patients  (15.5%)  who
were  included  after  more  than  6  hours,  [12].
Although  IV  thrombolysis  can  be  performed  for  up  to  4
h  30  after  the  onset  of  the  ﬁrst  symptoms,  the  earlier  it
is  administered,  the  more  effective  it  is  [26].  For  MT,  the
results  are  probably  similar,  but  have  not  yet  been  conﬁrmed
in  the  literature.  In  any  case  reducing  the  delay  to  manage-
ment  makes  it  possible  to  treat  more  patients  by  increasing
the  number  of  patients  treated  in  the  6-hour  window.  Thus,
optimization  of  the  delay  to  IV  thrombolysis  and  MT  is  a
major  goal  [27].  Sending  patients  who  are  eligible  for  MT
directly  to  interventional  neuroradiology  centers  who  have
the  technique  at  their  disposal  will  gain  a  signiﬁcant  amount
of  time.  Prehospitalization  selection  scales  are  being
created  for  these  patients  [28,29].  A  NIHSS  score  ≥  9  points
in  the  ﬁrst  3  hours  and  ≥  7  between  3  and  6  hours  strongly
suggests  proximal  cerebral  artery  occlusion  [28].
Intravenous thrombolysis
There  are  ﬁve  published  studies  evaluating  MT  in  association
with  IV  thrombolysis  compared  to  IV  thrombolysis  alone.  In
most  cases  thrombolysis  was  administered  before  MT  (68  to
100%  depending  on  the  studies,  Table  2).  Under  no  condition
should  MT  delay  the  administration  of  IV  t-PA  within  4  h  30
after  the  onset  of  symptoms  in  the  absence  of  contraindica-
tions.
However,  the  efﬁcacy  of  MT  persists  in  the  sub-
group  of  patients  without  thrombolysis  (OR  =  2.06,  95%
CI  =  0.69—6.13  in  MR  CLEAN  with  55  patients;  OR  =  2.57,  95%
CI  =  1.12—5.87  in  ESCAPE  with  45  patients)  [11,12].  Although
these  results  should  be  the  subject  of  a  speciﬁc  trial,  primary
thrombectomy  should  be  proposed  to  patients  in  whom  IV
thrombolysis  is  contraindicated  (grade  A  according  to  the
European  Stroke  Organization  guidelines)  [30].
Tandem occlusion
Endovascular  management  of  tandem  occlusions  (intracra-
nial  occlusion  associated  with  an  extracranial  occlusion  due
to  artherosclerotic  plaque  or  dissection)  has  not  been  clearly
established  (Fig.  2).  Treatment  is  more  difﬁcult  and  can
a  require  placement  of  a  carotid  stent  associated  with
emergency  antiplatelet  treatment  increasing  the  risk  of
hemorrhage  [31].  However,  without  extracranial  ICA  treat-
ment,  the  risk  of  thromboembolic  recurrence  persists  for
several  days,  especially  since  an  endarterectomy  cannot  be
rapidly  performed  in  case  of  IV  thrombolysis  [32].
Except  for  SWIFT  PRIME  the  presence  of  tandem  occlu-
sion  was  not  an  exclusion  criteria.  Although  there  were  a
relatively  small  number  of  patients,  the  functional  bene-
ﬁt  with  MT  was  signiﬁcant  (OR  =  1.43,  95%  CI  =  0.78—2.64
in  MR  CLEAN  with  146  patients;  OR  =  9.6,  95%  CI  =  2.6—35.5
in  ESCAPE;  OR  =  4.3,  95%  CI  =  1.5—12.5  in  REVASCAT).  Tan-
dem  stenoses/occlusions  can  be  treated  by  stenting  of  the
a
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ervical  segment  of  the  ICA  and  by  intracranial  thrombec-
omy  with  a  reasonable  risk.
evere neurological deﬁcits
hatever  the  severity  of  the  neurological  deﬁcit,  MT  is  ben-
ﬁcial.  Indeed,  except  for  the  SWIFT  PRIME  study  whose
nitial  maximum  NIHSS  score  was  29,  there  was  no  upper
imit  in  the  4  trials.  The  beneﬁt  of  MT  persists  in  patients
resenting  with  a  severe  neurological  deﬁcit  with  a  NIHSS
core  ≥  17  (OR  =  1.85,  95%  CI  =  1.06—3.21  in  the  MR  CLEAN
tudy  with  183  patients;  OR  =  2.4,  95%  CI  =  1.1—5.3  in  the
SCAPE  trial;  OR  =  2.0,  95%  CI  =  1—4  in  the  REVASCAT  study
ith  114  patients).  MT  should  therefore  be  proposed  what-
ver  the  initial  clinical  severity,  especially  since  a certain
umber  of  patients  with  proximal  artery  occlusion  presented
ith  a  low  NIHSS  score  in  the  ﬁrst  hours  [29,33].
lderly patients (80 years or older)
nlike  IV  thrombolysis  which  does  not  have  an  authorization
n  patients  over  the  age  of  80  years  but  in  whom  a  certain
umber  of  results  suggest  it  would  be  beneﬁcial  [34,35],
T  provides  a  functional  beneﬁt  whatever  the  age  of  the
atient  because  there  was  no  upper  age  limit  in  the  MR
LEAN,  ESCAPE  or  EXTEND-IA  (Table  1).  The  age  was  limited
o  80  years  in  the  SWIFT  PRIME  study  and  85  in  the  REVASCAT
tudy.  In  MR  CLEAN,  16%  of  patients  were  over  80  years  and
he  beneﬁt  persisted  (OR  =  3.24,  95%  CI  =  1.21—8.62)  [11].  In
he  ESCAPE  study,  a beneﬁt  was  also  reported  (OR  =  3.0,  95%
I  =  1.3—6.8)  [12].  Age  is  therefore  not  a  factor  of  exclusion
or  MT.
ocal or general anesthesia
ifferent  types  of  anesthesia  can  be  considered  (local  anes-
hesia,  conscious  sedation  and  general  anesthesia).  The
nesthesia  protocol  for  a  MT  procedure  has  not  been  clearly
eﬁned  and  is  a  subject  of  debate.  However,  at  present,  the
eurological  prognosis  seems  to  favor  conscious  sedation.
evertheless,  it  is  not  known  whether  preventive  measures
gainst  hypotension  were  performed  at  induction.  In  the
R  CLEAN  study,  79/216  patients  received  general  anes-
hesia,  and  137  received  conscious  sedation.  Six  procedures
ere  converted  to  general  anesthesia  (4.4%).  The  beneﬁts
f  MT  were  greater  in  patients  who  received  local  anesthe-
ia  (38%  of  autonomous  patients  received  local  anesthesia,
R  =  2.79,  95%  CI  =  1.7—4.59;  vs.  23%  general  anesthesia,
R  =  1.09,  95%  CI  =  0.56—2.12)  [36].  MT  was  begun  later  with
eneral  anesthesia  (162  ±  69  vs.  134  ±  60  min).  On  the  other
and  the  delay  to  revascularization  and  the  duration  of  the
rocedure  were  not  statistically  different  between  the  two
roups.  Nevertheless,  this  is  a  subgroup  analysis  with  all  of
he  associated  methodological  limitations.  The  most  severe
atients  were  probably  more  frequently  treated  by  general
nesthesia.  The  beneﬁts  of  local  anesthesia  were  also  found
n  a  meta-analysis  [37].  There  are  two  ongoing  trials  to
etermine  the  best  anesthesia  protocol  for  MT  (ANSTROKE,
edation  versus  general  anesthesia  for  endovascular  therapy
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Figure 2. A 62-year-old patient with high blood pressure presenting with a left brachio-facial deﬁcit at 17 h 15 with a notion of cervicalgia
(NIHSS 16). Unenhanced head CT performed at 18 h 29 shows spontaneous hyperattenuating area of the M1 right segment (arrow, a) with
no parenchymal abnormalities (b, c). IV thrombolysis at 19 h 10. After puncture of the femoral artery under local anesthesia at 19 h 18,
angiogram shows tandem occlusion associating occlusion of the post-bulbar territory of the carotid artery by dissection (arrows, d) and M1
segment occlusion (arrow, e). Placement of a catheter in the petrous segment of the ICA above the dissection (arrow, f), and placement
of the ‘‘stent retriever’’ (wide arrow, f) within the thrombus at 20 h 11. Recanalisation of more than 50% of the territory of the middle
cerebral artery (TICI 2b) (g, h) after removal of the ‘‘stent retriever’’. Left carotid artery angiogram does not show any functional anterior
communicating artery (i). Self-expandable carotid stents are released into the cervical segment of the right ICA and 500 mg of aspirin is
administered intravenously (arrows, j, k). Unenhanced head CT is performed at 24 hours showing superﬁcial ischemia of the territory of the
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iight middle cerebral artery (l—n), and the Doppler shows satisfact
n  acute  stroke  —  impact  on  neurological  outcome  in  Swe-
en,  NCT02317237;  GOLIATH,  general  or  local  anesthesia  in
ntra-arterial  therapy  in  Denmark,  NCT01872884).
To  date,  general  anesthesia  should  therefore  be  limited
o  agitated  or  confused  patients  (Glasgow  score  ≤  8)  with
 high  inhalation  or  hypoxia  risk.  These  conditions  are
bviously  more  frequent  in  posterior  circulation  occlusions.
owever,  the  American  Heart  Association  (AHA)  guidelines
o  not  recommend  one  technique  rather  than  another,  but
nsist  on  the  importance  of  rapid  and  coordinated  manage-
ent  by  healthcare  providers.
hrombectomy of basilar occlusionshe  spontaneous  prognosis  of  basilar  artery  occlusions  is
atastrophic  with  a  mortality  rate  of  80—90%,  in  partic-
lar  in  the  absence  of  recanalization  [38].  Intravenous
t
i
s
sent patency (o).
hrombolysis  is  the  only  ﬁrst-line  treatment  for  the  ﬁrst  4
 30  after  the  onset  of  symptoms,  but  its  efﬁcacy  is  also
imited  by  a  low  rate  of  recanalization  [5].
Currently  there  are  no  robust  results  on  ‘‘stent  retriev-
rs’’  MT  in  this  location.  The  French  trial  Thrombectomie
es  artères  cérébrales  (THRACE)  included  basilar  occlu-
ions  and  may  show  that  MT  is  beneﬁcial,  however  only
.5%  of  patients  have  been  included.  The  trial  Basilar
rtery  International  Cooperation  Study  (BASICS)  evaluating
‘stent  retrievers’’  associated  with  thrombolysis  compared
o  thrombolysis  alone  within  6  hours  after  the  onset  of  symp-
oms  is  ongoing  [39]. In  2009,  the  international  prospective
ASICS  register  reported  certain  results.  The  592  patients
ncluded  in  the  BASICS  study  were  divided  into  three
reatment  groups  (antithrombotics,  IV  thrombolysis  and
ntra-arterial  treatment)  [40]. None  of  the  therapeutic
trategies  was  found  to  be  signiﬁcantly  better.  However,  the
tatus  of  the  patients  in  the  endovascular  group  was  more
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Figure 3. A 42-year-old patient presenting with sudden coma at 10 h 15 while jogging. Unenhanced head CT at 11 h 20 shows spontaneous
hyperattenuating area of the basilar artery (arrow, a) and CT angiography conﬁrms basilar artery occlusion (arrow, b). Arrival in the
interventional neuroradiology unit at 12 h 30, initial angiogram conﬁrms occlusion of the dominant right vertebral artery at its origin
probably due to dissection (c) and selective injection of the left vertebral artery conﬁrms complete occlusion of the basilar top (arrow, d).
The dissection is crossed with an intermediate catheter (arrow, e, f), and the basilar artery is recanalized (TICI 2b) by MT at 13 h 25, or
toms 
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t55 min after arrival of the patient, 3 h 10 after the onset of symp
partial recanalization of the right vertebral artery (h).
often  severe  and  they  were  treated  later  than  the  thrombo-
lysis  group.  Moreover,  ‘‘stent  retrievers’’  were  not  available
when  this  study  was  performed.  The  results  should  there-
fore  be  interpreted  with  caution  because  they  are  based  on
a  register  with  all  its  associated  methodological  limitations.
In  the  recently  published  ENDOSTROKE  register,  the  rate  of
effective  recanalization  (TICI  ≥  2b)  was  79%  with  a  positive
outcome  at  3  months  in  34%  of  the  cases  [41].  A  system-
atic  review  of  the  literature  and  a  meta-analysis  of  acute
basilar  artery  occlusion  treated  by  ‘‘stent  retrievers’’  from
November  2010  to  April  2014  showed:
• effective  recanalization  (TICI  ≥  2b)  in  81%  (95%
CI  =  73—87);
• symptomatic  cerebral  hemorrhage  in  4%  (95%  CI  =  2—8);
• a  positive  clinical  outcome  (mRS  ≥  2  to  3  months)  in  42%
(95%  CI  =  36—48);
• mortality  rate  of  30%  (95%  CI  =  25—36)  [42].
Although  we  reported  reversible  ischemic  lesions  on  MR
following  early  reperfusion  [43,44],  the  initial  extent  of
ischemia  and  the  delay  to  recanalization  seem  to  be  the
two  main  criteria  directly  affecting  the  functional  prognosis
[45,46].  Although  ‘‘stent  retrievers’’  are  also  promising  for
a
a
t
u(g). No extracranial vertebral artery stenting is performed due to
osterior  circulation  and  while  waiting  for  the  results  of  the
HRACE  and  BASICS  studies,  basilar  artery  thrombectomy  is
ustiﬁed  because  of  a  positive  beneﬁt/risk  ratio  (grade  B
ccording  to  guidelines  from  the  European  Stroke  Organiza-
ion)  (Fig.  3) [30].
onclusion
echanical  thrombectomy  by  ‘‘stent  retrievers’’  associ-
ted  with  IV  thrombolysis  is  the  new  ﬁrst-line  treatment  of
schemic  stroke  with  proximal  intracranial  occlusion  within
he  ﬁrst  6  hours  after  the  onset  of  symptoms,  whatever
he  age  and  initial  severity  of  the  deﬁcit.  It  is  therefore
ssential  to  systematically  document  and  localize  arterial
cclusion  by  performing  vascular  imaging  during  the  ini-
ial  radiological  assessment.  CT  angiography  is  well  adapted
ecause  it  is  the  technique  used  in  most  trials.  To  guaran-
ee  these  results,  rapid  management  is  necessary  involving
ll  of  the  healthcare  providers  as  well  as  the  emergency
mbulance  team  to  transfer  patients  who  are  initially  hospi-
alized  in  centers  without  an  interventional  neuroradiology
nit.
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